Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines, has released its Form 10-Q report for the second quarter of 2025. The report provides a detailed overview of the company’s financial performance and key business activities for the six months ended June 30, 2025.
Financial Highlights
- Revenues: $0, The company reported no revenue for the six months ended June 30, 2025, compared to $33,000 for the same period in 2024.
- Operating Loss: $(6.4) million, The operating loss decreased from $(8.0) million in the six months ended June 30, 2024, to $(6.4) million in the same period in 2025, reflecting cost management efforts.
- Net Loss: $(1.4) million, The net loss for the…